Pr. Tim Hughes Chronic Myeloid Leukemia CML
''Professor Tim Hughes was promoted to Clinical Professor, University of Adelaide and was also awarded the 2006 Eric Susman Prize from the Royal Australasian College of Physicians for his original and groundbreaking research in chronic myeloid leukaemia (CML). His contributions include defining the importance of molecular monitoring in CML patients receiving kinase inhibitor therapy, showing that the mutation profile helps clinicians to choose the best kinase inhibitor to use and using pre-therapy kinase sensitivity to tailor drug dose for each patients. His work also led to a publication in the journal Nature describing the in-vivo kinetics of a human cancer.''
Extract of http://www.rah.sa.gov.au/cancer/haematology5.php
''Professor Tim Hughes from the Centre for Cancer Biology in Adelaide, who is an internationally renowned expert in CML treatment, presented research partially funded by the Foundation showing the exciting possibility that up to 50% of patients who have received the drug imatinib as treatment for CML may be able to discontinue this therapy and remain disease free. Professor Hughes and his team are undertaking detailed studies to predict which patients can safely stop the treatment and thereby reduce the potential impact of side-effects from long-term drug use. It also represents a potential major cost saving to the health system as imatinib currently costs $60 million to supply annually in Australia.''
Extract of http://www.leukaemia.org.au/web/news/docs/Carer0810web.pdf
Extract of http://www.rah.sa.gov.au/cancer/haematology5.php
''Professor Tim Hughes from the Centre for Cancer Biology in Adelaide, who is an internationally renowned expert in CML treatment, presented research partially funded by the Foundation showing the exciting possibility that up to 50% of patients who have received the drug imatinib as treatment for CML may be able to discontinue this therapy and remain disease free. Professor Hughes and his team are undertaking detailed studies to predict which patients can safely stop the treatment and thereby reduce the potential impact of side-effects from long-term drug use. It also represents a potential major cost saving to the health system as imatinib currently costs $60 million to supply annually in Australia.''
Extract of http://www.leukaemia.org.au/web/news/docs/Carer0810web.pdf
Pr. Timothy Hughes at BTG2011 VIDEO
Julye 30, 2011, TheMedalGroup
A molecular criteria have now been defined to guide decisions about if and when to use dasatinib or nilotinib VIDEO
June 11, 2011, ecancecr,tv
Practical recommendations for the management of CML patients: Interview with Prof. Timothy Hughes VIDEO
December 2010, iCMLf
Optimising Response and Managing Resistance to Treatment VIDEO
December 2010, iCMLf
ASH2010- New evidence of the superiority of nilotinib in imatinib VIDEO
December 2010, Médecine Plus
Adelaide researchers on road to myeloid leukemia cure
October 2009, NEWS.COM.AU
Julye 30, 2011, TheMedalGroup
A molecular criteria have now been defined to guide decisions about if and when to use dasatinib or nilotinib VIDEO
June 11, 2011, ecancecr,tv
Practical recommendations for the management of CML patients: Interview with Prof. Timothy Hughes VIDEO
December 2010, iCMLf
Optimising Response and Managing Resistance to Treatment VIDEO
December 2010, iCMLf
ASH2010- New evidence of the superiority of nilotinib in imatinib VIDEO
December 2010, Médecine Plus
Adelaide researchers on road to myeloid leukemia cure
October 2009, NEWS.COM.AU
